Neurava Awarded $4 Million NIH Blueprint Optimizer Award to Develop SUDEP Risk Stratification Algorithm
BALTIMORE, April 23, 2026 /PRNewswire/ — Neurava Inc., an innovative medtech startup focused on advanced wearable monitoring solutions for epilepsy, today announced that it has been awarded a $4 million NIH Blueprint MedTech Optimizer award to support the development of a Sudden Unexpected Death in Epilepsy (SUDEP) risk stratification and forecasting algorithm. The up-to four-year award will enable Neurava to develop, validate, and integrate a first-in-class quantitative SUDEP risk assessment platform, with the goal of advancing to first-in-human clinical trials.
The NIH Blueprint MedTech program is a highly competitive, trans-agency initiative designed to accelerate the development of promising neurotechnology innovations toward clinical impact. Neurava’s selection reflects the urgent unmet need for objective, data-driven approaches to understanding and mitigating SUDEP risk, one of the leading causes of mortality among people with epilepsy.
